1. Concomitance of monosomal karyotype with at least 5 chromosomal abnormalities is associated with dismal treatment outcome of AML patients with complex karyotype – retrospective analysis of Polish Adult Leukemia Group (PALG)
- Author
-
Monika Siemieniuk-Rys, Ewa Duszenko, Ewa Wawrzyniak, Marzena Watek, Aleksandra Kotkowska, Katarzyna Skonieczka, Wanda Knopinska-Posluszny, Sebastian Grosicki, Aleksandra Gołos, Jadwiga Hołojda, Justyna Rybka, Jerzy Holowiecki, Agnieszka Pluta, Barbara Pienkowska-Grela, Malgorzata Wach, Lidia Gil, Agnieszka Wierzbowska, Tadeusz Robak, Mariola Iliszko, Anna Jaskowiec, Renata Woroniecka, Anna Jachalska, Malgorzata Jarmuz-Szymczak, Olga Haus, Maria Czyżewska, Anna Ejduk, Barbara Mucha, Marta Szarawarska, Anna Przybylowicz-Chalecka, Agnieszka Kopacz, and Agnieszka Klonowska
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Monosomy ,Pathology ,medicine.medical_treatment ,Karyotype ,Hematopoietic stem cell transplantation ,Biology ,Gastroenterology ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Complex Karyotype ,medicine ,Humans ,Transplantation, Homologous ,Cladribine ,Survival analysis ,Aged ,Retrospective Studies ,Aged, 80 and over ,Chromosome Aberrations ,Hematopoietic Stem Cell Transplantation ,Myeloid leukemia ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,Combined Modality Therapy ,Survival Analysis ,Leukemia, Myeloid, Acute ,Regimen ,Leukemia ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Female ,Poland ,Biomarkers ,030215 immunology ,medicine.drug - Abstract
Monosomal karyotype (MK) and complex karyotype (CK) are poor prognostic factors in acute myeloid leukemia (AML). A comprehensive analysis of cytogenetic and clinical factors influencing an outcome of AML-CK+ was performed. The impact of cladribine containing induction on treatment results was also evaluated. We analyzed 125 patients with AML-CK+ treated within PALG protocols. MK was found in 75 (60%) individuals. The overall complete remission (CR) rate of 66 intensively treated patients was 62% vs. 28% in CK+ MK− and CK+ MK+ group (p = .01). No difference in CR rate was observed between DA and DAC arms. The overall survival (OS) in intensively treated patients was negatively influenced by MK, karyotype complexity (≥5 abnormalities), and WBC >20 G/L in multivariate analysis. The addition of cladribine to DA regimen improved OS only in MK− but not in MK+ group. In conclusion, concomitance of MK with ≥5 chromosomal abnormalities is associated with dismal treatment outcome in AMK-CK+.
- Published
- 2016
- Full Text
- View/download PDF